Nuvectis Pharma (NVCT) Corporate Presentation summary

Precision medicine strategy and pipeline

• Focus on developing novel, targeted therapies for serious oncology conditions with unmet medical need.

• NXP900, a highly selective YES1/SRC inhibitor, is the lead candidate with completed Phase 1a and DDI studies and an ongoing Phase 1b program.

• NXP900 discovered at University of Edinburgh; unique mechanism fully shuts down SRC pathway.

• Management team has a strong track record, including three approved drugs in four indications and multiple strategic deals.

• Cash runway extends into 2027, supporting ongoing development.

NXP900 clinical and preclinical data

• Phase 1a study in solid tumors showed NXP900 was well tolerated, with no DLT identified and >90% SRC inhibition at ≥150 mg/day.

• Most common adverse events were mild to moderate, including diarrhea, fatigue, and nausea.

• DDI study in healthy volunteers showed NXP900 is a weak inhibitor of CYP3A and CYP2B6, with no serious adverse events.

• Preclinical models demonstrate potent activity in tumors with YES1 amplification and FAT1 mutations.

• NXP900 is more selective and potent than prior SRC inhibitors, such as saracatinib.

Market opportunity and development plans

• NXP900 targets large patient populations in NSCLC and other solid tumors, with an estimated 45,000 addressable patients in NSCLC alone.

• Phase 1b program includes single agent and planned combination studies with EGFR/ALK inhibitors to address resistance in NSCLC.

• Hippo pathway and YES1/SRC alterations are key inclusion criteria for ongoing trials.

• Additional market opportunities exist in bladder, head and neck, and esophageal cancers with relevant genetic alterations.

• NXP800, another pipeline asset, will not be pursued in ARID1a-mutated ovarian cancer but may be evaluated in other indications.